Towards Healthcare
Cancer Biopsy Market Size Leads at 18.84% CAGR by 2034

Cancer Biopsy Market 2025 Analysis Instrument Segment Dominates, Liquid Biopsy Kits Rising Fast

According to market projections, the global cancer biopsy market, valued at USD 30.81 billion in 2024, is anticipated to reach USD 163.29 billion by 2034, growing at a CAGR of 18.84% over the next decade. Increasing advancements in biopsy technologies and widespread adoption of minimally invasive procedures are driving the global market. And, North America dominated the market due to growing demand for personalized medicine and awareness regarding cancer and biopsy techniques.

  • Insight Code: 5958
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The cancer biopsy market is projected to reach USD 163.29 billion by 2034, growing at a CAGR of 18.84% from 2024 to 2034.

North America is currently leading the cancer biopsy market due to rising novel developments in precision medicines and growing awareness about cancer and liquid biopsy.

The cancer biopsy market includes six segments such as by technique type, by product type, by cancer type, by application, by end user, and by region.

Some key players include QIAGEN N.V., Illumina, Inc., Guardant Health, Inc., Exact Sciences Corporation, and Becton, Dickinson and Company (BD).

Key trends include progressing demand for minimally invasive procedures and personalized medicine, growth in programs related to cancer and adoption of liquid biopsy, and innovation in biopsy techniques and AI-driven diagnostic tools.

A biopsy is an approach in which a small sample of tissue is removed from the body for analysis under a microscope. 

The future of liquid biopsies will comprise improved sensitivity and accuracy, wider clinical application, and personalized cancer management.

NIH, CDC, US FDA, GOV.UK, NCI, ACTREC, TMC, MEDLINEPLUS, BHC, MYSCHEME